Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CKS1B | P61024 | 1/20 | 0.53 |
| ▸ | SKP1 | P63208 | 1/20 | 0.53 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475535 | 1.00 | GPR119 (0.59) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL25317395 | 0.97 | GPR119 (0.62) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL29475574 | 0.97 | GPR119 (0.62) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL15584576 | 0.91 | GPR119 (0.56) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL29660540 | 0.91 | GPR119 (0.56) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL5236610 | 0.91 | GPR119 (0.72) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL5233509 | 0.91 | MAPT (0.59) | GPR119PDK2MAPTALDH1A1MEN1 | |
| SCHEMBL5234323 | 0.90 | ABCB1 (0.56) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL15205720 | 0.90 | GPR119 (0.55) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL5235594 | 0.89 | GPR119 (0.69) | GPR119PDK2MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4217342-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | Neuropore Therapies, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507607-A | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | GPR119 867/4885PDK2 3003/4885MAPT 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.